Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop (2024)
Chapter: Appendix A: Statement of Task
Visit
NAP.edu/10766
to get more information about this book, to buy it in print, or to
download it as a free PDF.
Previous Chapter:
Proceedings of a Workshop
Appendix A
Next Chapter: Appendix B: Workshop Agenda
Suggested Citation:
"Appendix A: Statement of Task." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/27758.
Appendix A
Statement of Task
A National Academies of Sciences, Engineering, and Medicine planning committee will organize and host a 1.5-day public workshop that will examine opportunities to improve the care and outcomes for patients with cancer through public–private partnerships for clinical cancer research. The workshop will feature invited presentations and panel discussions on topics that may include:
- The potential for innovative public–private partnerships to expand and enhance clinical cancer research, including a greater emphasis on health equity.
- Strategies to further utilize the unique features of the NCI’s National Clinical Trials Network (NCTN), the NCI Community Oncology Research Program (NCORP), the Experimental Therapeutics Clinical Trials Network (ETCTN), the Cancer Screening Research Network (CSRN), and other relevant networks in these partnerships.
- The unique roles of potential participants in these partnerships, including the NCTN, NCORP, ETCTN, CSRN, and the Advanced Research Projects Agency for Health (ARPA-H), Foundation for the National Institutes of Health (FNIH) and other foundations, health systems, health insurers, professional societies, disease-focused groups, and small biotech and biopharmaceutical companies.
- The patient-centered research questions or types of studies that would be most suited for public–private partnerships, such as prevention trials, adjuvant trials, comparative effectiveness trials, and pragmatic
Suggested Citation:
"Appendix A: Statement of Task." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/27758.
- postmarket trials to enable evidence generation across the lifecycle of a drug.
- Opportunities to leverage public–private collaborations to enhance the integration of cancer research within health care delivery and to utilize data that are collected during routine care to answer important questions in cancer research.
- Potential challenges to conducting efficient clinical cancer research through public–private partnerships, and potential policies and strategies to overcome those challenges.
- Characteristics and principles of effective public–private collaborations in clinical research.
- Examples of past and ongoing public–private collaborations in oncology or other biomedical fields.
- Appropriate metrics to assess the effectiveness of public–private partnerships.
The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.